Lower plasma levels of glucose-dependent insulinotropic peptide (GIP) and pancreatic polypeptide (PP) in patients with ductal adenocarcinoma of the pancreas and their relation to the presence of impaired glucoregulation and weight loss

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F17%3A10360447" target="_blank" >RIV/00216208:11110/17:10360447 - isvavai.cz</a>

Alternative codes found

RIV/61383082:_____/17:00000287 RIV/00064165:_____/17:10360447

Result on the web

<a href="http://dx.doi.org/10.1016/j.pan.2016.12.004" target="_blank" >http://dx.doi.org/10.1016/j.pan.2016.12.004</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.pan.2016.12.004" target="_blank" >10.1016/j.pan.2016.12.004</a>

Result language

angličtina

Original language name

Lower plasma levels of glucose-dependent insulinotropic peptide (GIP) and pancreatic polypeptide (PP) in patients with ductal adenocarcinoma of the pancreas and their relation to the presence of impaired glucoregulation and weight loss

Original language description

Background: The changes in gastrointestinal hormones associated with pancreatic ductal adenocarcinoma (PDAC) in patients with impaired glucoregulation have yet to be evaluated. The aim of this study was to determine plasma concentrations of selected gastrointestinal hormones in PDAC patients with and without diabetes and to compare them with levels found in Type 2 diabetic patients without cancer. Methods: In this study we examined plasma concentrations of glucose-dependent insulinotropic peptide (GIP), glucagon-like peptide 1 (GLP-1), pancreatic polypeptide (PP), peptide YY (PYY) and neuropeptide Y (NPY), and cytokines leptin and adiponectin in 94 patients with histologically confirmed PDAC. Thirty-nine patients with Type 2 diabetes without PDAC and 29 healthy individuals with no evidence of acute or chronic diseases were examined as controls. Results: Significantly lower plasma concentrations of GIP were found in PDAC patients with new -onset diabetes/prediabetes (n = 76), or in those with normal glucose regulation (n = 18), compared to patients with Type 2 diabetes without PDAC and controls (15.5 (3.7-64.5) or 6.5 (1.7-24.5) vs. 39.8 (15.1 -104.7) and 28.8 (7.4-112.2) ng/L, p &lt; 0.001); the same relationship was observed for PP (38.9 (10.2 -147.9) or 28.1 (7.9-100.0) vs 89.1 (38.0-208.9) and 75.8 (30.1-190.6) ng/L, p &lt; 0.01), respectively. The lowest levels of GIP and PP concentrations were found in PDAC patients with new -onset diabetes/prediabetes and weight loss &gt; 2 kg (p &lt; 0.001). Conclusions: We conclude that GIP and PP plasma concentrations are lower in pancreatic cancer irrespective of the degree of glucose intolerance as compared to Type 2 diabetic patients and healthy controls. In new onset diabetes especially if associated with weight loss, these changes may represent a new clue for the diagnosis of PDAC.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30219 - Gastroenterology and hepatology

Project

<a href="/en/project/NT14254" target="_blank" >NT14254: Early Diagnosis of Pancreatic Adenocarcinoma: Surface Proteases and Specific Biomarkers</a><br>

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2017

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Pancreatology

ISSN

1424-3903

e-ISSN

—

Volume of the periodical

17

Issue of the periodical within the volume

1

Country of publishing house

CH - SWITZERLAND

Number of pages

6

Pages from-to

89-94

UT code for WoS article

000393634200018

EID of the result in the Scopus database

2-s2.0-85008194787